One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol.

Yousuf Muhammad; Fathima Saubia; Alsugair Ali Khalid A; Wu Samuel J; Abdelmagid Maymona G; Patel Shraddha P; Faldu Priyansh C; Abdelaziz Rania M; Csizmar Clifford M; Mangaonkar Abhishek A; Zepeda Mendoza Cinthya J; Reichard Kaaren K; Viswanatha David S; He Rong; Pardanani Animesh; Gangat Naseema; Patnaik Mrinal S; Tefferi Ayalew

Blood cancer journal 2026

Open on PubMed

Blood Cancer Journal - One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models...

1 Figure Extracted

Fig. 1 PMC

Overall survival data in 536 Mayo Clinic patients with chronic myelomonocytic leukemia, stratified by the number of TET2 mutations—calculated from t...

One vs. 2 vs. &#x2265;3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol.

One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol.